Loading...
XSTO
CMH
Market cap160mUSD
, Last price  
SEK
Name

Chordate Medical Holding publ AB

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
57.24%
Rev. gr., 5y
-10.60%
Revenues
665k
-31.92%
645,145165,913995,321945,1141,163,725618,007882,046108,517976,281664,687
Net income
-27m
L-6.62%
-16,141,656-13,707,463-23,355,859-26,685,528-24,889,160-19,758,879-21,766,276-27,942,965-29,186,675-27,253,583
CFO
-24m
L-10.47%
-12,423,324-9,639,325-18,990,959-18,994,702-16,945,517-17,429,799-20,336,340-24,979,043-27,263,296-24,407,728

Profile

Chordate Medical Holding AB (publ), a medical technology company, develops products and solutions for the treatment of chronic migraine and rhinitis in Sweden. It focuses on the ear-nose and throat area. The company was founded in 2005 and is based in Kista, Sweden.
IPO date
Mar 08, 2017
Employees
3
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
665
-31.92%
976
799.66%
109
-87.70%
Cost of revenue
(1,324)
1,654
21,124
Unusual Expense (Income)
NOPBT
1,989
(678)
(21,015)
NOPBT Margin
299.17%
Operating Taxes
(81)
Tax Rate
NOPAT
1,989
(678)
(20,934)
Net income
(27,254)
-6.62%
(29,187)
4.45%
(27,943)
28.38%
Dividends
Dividend yield
Proceeds from repurchase of equity
21,362
33,200
65
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
1
1
Net debt
(2,530)
(8,546)
(3,758)
Cash flow
Cash from operating activities
(24,408)
(27,263)
(24,979)
CAPEX
(1,102)
(378)
(389)
Cash from investing activities
(2,880)
(1,158)
(389)
Cash from financing activities
21,362
33,200
65
FCF
1,576
(796)
(21,064)
Balance
Cash
2,530
8,455
3,676
Long term investments
91
82
Excess cash
2,496
8,497
3,752
Stockholders' equity
(16,169)
345,604
(248,072)
Invested Capital
25,364
6,589
259,145
ROIC
12.45%
ROCE
21.63%
EV
Common stock shares outstanding
1,025
224,513
415
Price
Market cap
EV
EBITDA
4,208
559
(18,562)
EV/EBITDA
Interest
7
81
Interest/NOPBT